Beta-endorphin and cholecystokinin 8 concentrations in peripheral blood mononuclear cells of autistic children
Child; Female; Humans; Male; Reference Values; adolescent; Preschool; infant; beta-Endorphin/blood; Biomarkers of Pain; Child Development Disorders; Sincalide/blood; Monocytes/metabolism; Autistic Disorder/blood/diagnosis/psychology; Pervasive/blood/diagnosis/psychology
beta-Endorphin (beta-EP) and cholecystokinin 8 (CCK-8) concentrations in peripheral blood mononuclear cells were measured in 12 drug-free autistic (AU) children, in 10 drug-free children with pervasive developmental disorders (PDD) and in 11 healthy controls. The aim of the study was to see whether or not there was an alteration of beta-EP and CCK-8 concentrations in this peripheral compartment, in which it has been suggested that secretion and regulation of the two peptides mimic those of neurons in the central nervous system. Mean beta-EP values were significantly higher in AU than in PDD and control children, while there were no differences in CCK-8 values of the three groups.
1997
Brambilla F; Guareschi-Cazzullo A; Tacchini C; Musetti C; Panerai AE; Sacerdote P
Neuropsychobiology
1997
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Journal Article
<a href="http://doi.org/10.1159/000119322" target="_blank" rel="noreferrer">10.1159/000119322</a>
Non-communicating children's pain checklist: better pain assessment for severely disabled children
Child; Pain Measurement; Pain; Child Psychology; Developmental Disabilities; Mental Disorders; Cognition Disorders; Minors; Child Development Disorders; Mental Retardation; Child Behavior Disorders; Child Development Deviations
Advances in the treatment of pain for children with severe disabilities have lagged behind that for other children. This is due, in part, to a lack of valid assessment tools for their pain. The non-communicating children's pain checklists are observational pain tools that were developed specifically for children with severe disabilities who are unable to communicate verbally. The non-communicating children's pain checklist-revised has been validated for use with a wide range of pain types in the home. The non-communicating children's pain checklist-postoperative version is used for pain following surgery in the hospital setting. Scores for determining the presence of pain have also been developed. They are appropriate for children with varying degrees of physical, cognitive and communicative impairments.
2003
Breau LM
Expert Review Of Pharmacoeconomics And Outcomes Research
2003
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Journal Article
<a href="http://doi.org/10.1586/14737167.3.3.327" target="_blank" rel="noreferrer">10.1586/14737167.3.3.327</a>
Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders
Child; Female; Humans; Male; Treatment Outcome; Double-Blind Method; Preschool; Child Development Disorders; Autistic Disorder/drug therapy; Dopamine Antagonists/therapeutic use; Serotonin Antagonists/therapeutic use; Aggression/drug effects; Antipsychotic Agents/adverse effects/pharmacology/therapeutic use; Irritable Mood/drug effects; Pervasive/drug therapy; Risperidone/adverse effects/pharmacology/therapeutic use
OBJECTIVE: To investigate the efficacy and safety of risperidone for the treatment of disruptive behavioral symptoms in children with autism and other pervasive developmental disorders (PDD). METHODS: In this 8-week, randomized, double-blind, placebo-controlled trial, risperidone/placebo solution (0.01-0.06 mg/kg/day) was administered to 79 children who were aged 5 to 12 years and had PDD. Behavioral symptoms were assessed using the Aberrant Behavior Checklist (ABC), Nisonger Child Behavior Rating Form, and Clinical Global Impression-Change. Safety assessments included vital signs, electrocardiogram, extrapyramidal symptoms, adverse events, and laboratory tests. RESULTS: Subjects who were taking risperidone (mean dosage: 0.04 mg/kg/day; 1.17 mg/day) experienced a significantly greater mean decrease on the irritability subscale of the ABC (primary endpoint) compared with those who were taking placebo. By study endpoint, risperidone-treated subjects exhibited a 64% improvement over baseline in the irritability score almost double that of placebo-treated subjects (31%). Risperidone-treated subjects also exhibited significantly greater decreases on the other 4 subscales of the ABC; on the conduct problem, insecure/anxious, hyperactive, and overly sensitive subscales of the Nisonger Child Behavior Rating Form (parent version); and on the Visual Analog Scale of the most troublesome symptom. More risperidone-treated subjects (87%) showed global improvement in their condition compared with the placebo group (40%). Somnolence, the most frequently reported adverse event, was noted in 72.5% versus 7.7% of subjects (risperidone vs placebo) and seemed manageable with dose/dose-schedule modification. Risperidone-treated subjects experienced statistically significantly greater increases in weight (2.7 vs 1.0 kg), pulse rate, and systolic blood pressure. Extrapyramidal symptoms scores were comparable between groups. CONCLUSIONS: Risperidone was well tolerated and efficacious in treating behavioral symptoms associated with PDD in children.
2004
Shea S; Turgay A; Carroll A; Schulz M; Orlik H; Smith I; Dunbar F
Pediatrics
2004
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Journal Article
<a href="http://doi.org/10.1542/peds.2003-0264-F" target="_blank" rel="noreferrer">10.1542/peds.2003-0264-F</a>
The use of the Impact on Sibling scale with families of children with chronic illness and developmental disability
Child; Female; Humans; Male; Socioeconomic Factors; Sibling Relations; Psychometrics; adolescent; Preschool; Adaptation; Psychological; infant; Chronic disease; Parents/psychology; Child Development Disorders; Developmental Disabilities/psychology; Siblings/psychology; Pervasive/psychology
OBJECTIVE: This study evaluated the Impact on Sibling scale, a six-item measure of parents' perception of the effects of a child's illness on healthy siblings. METHODS: Participants were 122 parents of a child with chronic illness, developmental disability, or autism spectrum disorder, and a well sibling aged 4-13 years. Parents completed the Impact on Sibling scale and the Child Behavior Checklist about the sibling, and completed the revised Impact on Family scale and the Brief Symptom Inventory about themselves. RESULTS: The Impact on Sibling score was correlated with measures of sibling, parent and family functioning. The internal consistency of the Impact on Sibling scale was higher for families with children with chronic illness compared with the other two diagnostic groups. CONCLUSION: The Impact on Sibling scale is a brief set of items that can help identify siblings who are negatively affected by a brother/sister's illness. Findings support further research on the Impact on Sibling scale, particularly with families of children with chronic illnesses.
2009
Kao B; Plante W; Lobato D
Child: Care, Health And Development
2009
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Journal Article
<a href="http://doi.org/10.1111/j.1365-2214.2009.00944.x" target="_blank" rel="noreferrer">10.1111/j.1365-2214.2009.00944.x</a>
Life at the interface: adults with "pediatric" disorders of the nervous system
Child; Humans; Neoplasms; Adult; Cerebral Palsy; Epilepsy; Cystic Fibrosis; Heart Defects; Child Development Disorders; Congenital; Pervasive
The increasing longevity of patients with congenital and developmental disorders of the nervous system reflects the palliative and social success of pediatrics in the past 2 decades. This success has resulted in an increasing number of adult patients with residua or sequelae of childhood disease and/or its treatment. It is critically important that residencies and subspecialty fellowships train a cadre of physicians to prepare patients and families for the transition of children with special health care needs to adulthood and to attend to their unique medical, psychological, and social concerns. Health services and education research must better define the needs of this growing population and the best ways to educate their physicians and families and empower them to become as independent as their fullest potential allows.
2013-08
Schor NF
Annals Of Neurology
2013
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Journal Article
<a href="http://doi.org/10.1002/ana.23910" target="_blank" rel="noreferrer">10.1002/ana.23910</a>